Live Analyst Rating Changes 18364 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/David Amsellem
PIPR

David Amsellem

Piper Sandler
Wall Street Analyst
★★★★☆
#504
on 13Foresight · ranked by our own returns
64%
Success Rate
+5.0%
Average Return
44 of 69 calls profitable · +1.6% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 64% of David Amsellem's ratings turned a profit when each position was held for 1 year — averaging +5.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

185 Buy 28 Hold 2 Sell
David's Stock Coverage 36 ratings · 2026-08-06
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
AMGN
Amgen
 Aug 05, 2026 BUY Buy
-23.8% avg upside
57 analysts
$427.00
4.63% Upside
 +0.0% ·
JAZZ
Jazz Pharmaceuticals
 Aug 04, 2026 BUY Strong Buy
-9.3% avg upside
35 analysts
$310.00
18.46% Upside
 -0.0% ·
NBIX
Neurocrine
 Jul 31, 2026 BUY Strong Buy
+15.2% avg upside
37 analysts
$210.00
30.07% Upside
 +0.0% ·
CORT
Corcept Therapeutics
 Jul 30, 2026 BUY Buy
-47.1% avg upside
15 analysts
$165.00
49.09% Upside
 -6.5% ·
ALKS
Alkermes
 Jul 28, 2026 BUY Strong Buy
-16.4% avg upside
34 analysts
$65.00
31.02% Upside
 -1.8% ·
BIIB
Biogen
 Jul 28, 2026 BUY Strong Buy
+22.3% avg upside
52 analysts
$225.00
8.80% Upside
 +0.5% ·
ABBV
AbbVie
 Jul 28, 2026 BUY Strong Buy
-3.2% avg upside
46 analysts
$298.00
21.11% Upside
 -7.3% ·
TEVA
Teva Pharmaceutical
 Jul 28, 2026 BUY Buy
-13.6% avg upside
39 analysts
$44.00
26.63% Upside
 +7.5% ·
BMY
Bristol-Myers Squibb
 Jul 28, 2026 BUY Buy
-4.5% avg upside
42 analysts
$75.00
17.83% Upside
 +3.6% ·
SUPN
Supernus Pharmaceuticals
 Jul 27, 2026 BUY Strong Buy
+21.4% avg upside
9 analysts
$66.00
40.68% Upside
 -4.9% ·
DFTX
Definium Therapeutics
 Jul 24, 2026 BUY Strong Buy
+3.5% avg upside
21 analysts
$73.00
64.53% Upside
 +2.8% ·
AMRX
Amneal Pharmaceuticals
 Jul 20, 2026 BUY Strong Buy
-5.0% avg upside
18 analysts
$17.00
7.83% Downside
 +5.6% ·
AXSM
Axsome Therapeutics
 Jul 14, 2026 BUY Strong Buy
+9.5% avg upside
29 analysts
$258.00
21.31% Upside
 -9.6% ·
VTRS
Viatris
 Jun 04, 2026 HOLD Buy
+31.7% avg upside
21 analysts
$12.00
32.02% Downside
 +10.9% ·
INDV
Indivior
 May 22, 2026 BUY Strong Buy
-3.2% avg upside
10 analysts
$59.00
52.32% Upside
 +4.1% ·
AQST
Aquestive Therapeutics
 May 15, 2026 BUY Strong Buy
+136.8% avg upside
10 analysts
$8.00
113.02% Upside
 -10.3% ·
FENC
Fennec Pharmaceuticals
 May 15, 2026 BUY Strong Buy
+54.0% avg upside
9 analysts
$18.00
71.01% Upside
 -1.8% ·
AMPH
Amphastar Pharmaceuticals
 May 11, 2026 HOLD Hold
+29.6% avg upside
11 analysts
$21.00
3.68% Upside
 +9.7% ·
OGN
Organon
 Apr 28, 2026 HOLD Sell
+9.5% avg upside
9 analysts
$14.00
3.22% Upside
 +1.9% ·
COLL
Collegium Pharmaceutical
 Apr 23, 2026 HOLD Strong Buy
+17.9% avg upside
8 analysts
$44.00
23.20% Upside
 -4.1% ·
ANIP
ANI Pharmaceuticals
 Apr 23, 2026 BUY Strong Buy
+28.7% avg upside
11 analysts
$111.00
39.05% Upside
 +1.5% ·
HRMY
Harmony Biosciences Holdings
 Apr 22, 2026 BUY Strong Buy
+26.1% avg upside
13 analysts
$46.00
20.31% Upside
 +19.6% ·
PTHS
Pelthos Therapeutics
 Apr 20, 2026 BUY Strong Buy
+98.9% avg upside
8 analysts
$48.00
68.25% Upside
 +22.4% ·
XERS
Xeris Pharmaceuticals
 Nov 07, 2025 HOLD Strong Buy
+18.5% avg upside
10 analysts
$8.00
1.41% Downside
 -3.1% ·
PCRX
Pacira Pharmaceuticals
 Nov 07, 2024 HOLD Buy
+54.3% avg upside
21 analysts
$12.00
51.83% Downside
 +24.6% ·
TSE:BHC
Bausch Health Companies
 Oct 31, 2024 SELL Buy
+553.5% avg upside
29 analysts
$4.20
52.16% Downside
 +22.9% ·
IRWD
Ironwood Pharma
 May 22, 2024 BUY Buy
+184.2% avg upside
23 analysts
$18.00
333.64% Upside
 -90.5% ·
TVRD
Tvardi Therapeutics
 May 14, 2024 HOLD Strong Buy
+816.3% avg upside
23 analysts
$12.00
499.92% Upside
 +1.1% ·
EGRX
Eagle Pharmaceuticals
 Aug 09, 2023 SELL Strong Sell
+48919.7% avg upside
2 analysts
$17.00
33233.39% Upside
 · ·
EVFM
Evofem Biosciences
 May 25, 2022 BUY Buy
+303979.5% avg upside
8 analysts
$2.00
23709.50% Upside
 · ·
YARW
Yarrow Bioscience
 Nov 10, 2021 BUY Strong Buy
-27.4% avg upside
9 analysts
$3.00
91.99% Downside
 · ·
BXRXQ
Baudax Bio
 May 06, 2021 BUY Strong Buy
+18749999900.0% avg upside
3 analysts
$175.00
17499999899.96% Upside
 · ·
NOVN
Novan
 Jan 05, 2020 HOLD Buy
6 analysts
$0.50
 · ·
PFE
Pfizer
 Jan 23, 2019 HOLD Buy
+30.9% avg upside
45 analysts
 — +0.1% ·
TLPH
Talphera
 Oct 12, 2017 HOLD Buy
+247.9% avg upside
15 analysts
$2.00
48.20% Upside
 · ·
WINT
Windtree Therapeutics
 Nov 11, 2013 BUY Strong Buy
+3458233.3% avg upside
6 analysts
$6.00
2999900.04% Upside
 · ·
🔒 31 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
David Amsellem — Frequently Asked Questions
How accurate are David Amsellem's stock ratings?
Based on the calls 13Foresight could measure, about 65% of David's ratings were profitable over a one-year hold, with an average return of +5.3% per rating, or +1.8% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is David ranked on 13Foresight?
David Amsellem is currently ranked #504 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does David cover?
David most recently has ratings on AMGN, JAZZ, NBIX, CORT, ALKS, BIIB, ABBV, TEVA, BMY, SUPN, DFTX, AMRX and 24 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.